Unicycive Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Unicycive Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2020 to Q3 2024.
  • Unicycive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$4.1M, a 5.47% increase year-over-year.
  • Unicycive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$23M, a 18.1% increase year-over-year.
  • Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$30.5M, a 69.1% decline from 2022.
  • Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.1M, a 80.3% decline from 2021.
  • Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$10M, a 342% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$23M -$4.1M +$237K +5.47% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$23.2M $9.86M +$13.7M Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$36.9M -$21M -$6.39M -43.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$30.5M -$7.8M -$2.47M -46.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$28.1M -$4.33M +$1.22M +22% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$29.3M -$3.84M -$202K -5.56% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$29.1M -$14.6M -$11M -312% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$18.1M -$5.33M -$2.58M -93.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$15.5M -$5.56M -$356K -6.85% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$15.1M -$3.64M -$2.54M -231% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$12.6M -$3.54M -$2.57M -267% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$10M -$2.75M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$5.2M -$4.5M -641% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$1.1M -$762K -225% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$964K Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q3 2020 -$702K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$338K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.